Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haploidentical peripheral blood stem cells (haplo-PBSC) are hematopoietic stem cells collected from the peripheral blood of a donor who is a half-match (haploidentical) for the recipient's human leukocyte antigens (HLA). These cells are used in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with high-risk hematologic malignancies, such as acute leukemia, who lack a fully HLA-matched donor. The procedure typically involves mobilizing stem cells from the donor's bone marrow into the peripheral blood using growth factors like granulocyte colony-stimulating factor (G-CSF), followed by apheresis to collect the cells. Because of the HLA mismatch, specialized graft-versus-host disease (GVHD) prophylaxis, such as post-transplant cyclophosphamide (PTCy) or anti-thymocyte globulin (ATG), is often required to prevent severe immune reactions while maintaining the graft-versus-leukemia effect. This approach has significantly expanded the donor pool, as most patients have at least one haploidentical family member.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haploidentical peripheral blood stem cells.